Graft-versus-host disease overview: Difference between revisions
Shyam Patel (talk | contribs) (→Causes) |
Shyam Patel (talk | contribs) |
||
| Line 22: | Line 22: | ||
==Screening== | ==Screening== | ||
There is no role for screening for GvHD. However, there is a significant role for primary prevention in GvHD. | |||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
Revision as of 18:21, 12 June 2017
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease overview On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease overview |
|
Risk calculators and risk factors for Graft-versus-host disease overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack. It occurs in 4-70% of patients undergoing stem cell transplant.[1] Acute GvHD typically occurs within 100 days of transplant. Chronic HvHD occurs after 100 days from transplant.[2] Nearly 40% of paitents will develop some form of GvHD.[2]
Historical Perspective
Classification
Pathophysiology
Causes
The cause of GvHD is stem cell transplantation from an allogeneic donor.[2]
Differentiating [Disease] from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
There is no role for screening for GvHD. However, there is a significant role for primary prevention in GvHD.
Natural History, Complications, and Prognosis
Natural History
Complications
Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
References
- ↑ Al-Chaqmaqchi H, Sadeghi B, Abedi-Valugerdi M, Al-Hashmi S, Fares M, Kuiper R; et al. (2013). "The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease". PLoS One. 8 (4): e60367. doi:10.1371/journal.pone.0060367. PMC 3617218. PMID 23593203.
- ↑ 2.0 2.1 2.2 Meyer EH, Hsu AR, Liliental J, Löhr A, Florek M, Zehnder JL; et al. (2013). "A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease". Blood. 121 (24): 4955–62. doi:10.1182/blood-2013-03-489757. PMC 3682344. PMID 23652802.